Our Stocks and Sips evening with Imugene (ASX:IMU) featured a live Q&A and presentation with CEO and Managing Director Leslie Chong, who shared insights into Imugene's allogeneic CAR T platform, azer-cel - an "off-the-shelf" therapy reshaping cancer treatment. The discussion explored clinical progress, investment potential, and Imugene's role in the future of oncology, followed by drinks, gourmet food, and networking at the Sharewise office.

We hosted an after-work edition of Stocks and Sips featuring a live Q&A and presentation with Leslie Chong, Managing Director and CEO of Imugene (ASX:IMU) - a clinical-stage immuno-oncology company developing transformative treatments that activate the immune system against cancer.
Leslie shared insights into Imugene’s allogeneic CAR T platform, azer-cel - an “off-the-shelf” therapy designed to make cancer treatment more accessible and scalable - and discussed how the company is positioned at the forefront of the next generation of cell therapies.
The discussion covered:
Guests enjoyed complimentary drinks, gourmet food, and networking following the session at the Sharewise office.
Join us for an after-work edition of Stocks and Sips, featuring a live Q&A with Leslie Chong, CEO and Managing Director of Imugene (ASX:IMU), a clinical-stage immuno-oncology company developing transformative treatments that activate the immune system against cancer.
Enjoy drinks, canapés, and networking with investors and professionals following the session. Guests will also receive complimentary merch to take home.
This session is free to attend, but registration is essential.

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours and B-cell vaccine candidates. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Ms Chong has over 27 years of oncology experience in Phase I - III of clinical program development, including leadership role involvement in four marketed oncology products. She was previously at Genentech, Inc., in San Francisco before joining Imugene in 2015 in Sydney, Australia to develop immunotherapies in solid tumours and cellular therapy in hematology oncology.
























Attendance is free and spots are limited. Register to receive your QR code for check-in on the night.
Yes - free (limited spots available). Registration is essential.
Sharewise, Level 9, 68 Alfred St S, Milsons Point.
Drinks: Open bar. Food: Canapés served during networking.
Business casual.
The team behind Stocks and Sips works with clients every day on research, advisory and execution across ASX, US and global markets.